Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.7 |
mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.7 |
mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.05 | 0.7 |
mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |